c-Myc-targeting PROTAC based on a TNA-DNA bivalent binder for combination therapy of triple-negative breast cancer
X Li, Z Zhang, F Gao, Y Ma, D Wei, Z Lu… - Journal of the …, 2023 - ACS Publications
Triple-negative breast cancer (TNBC) is highly aggressive with a poor clinical prognosis and
no targeted therapy. The c-Myc protein is a master transcription factor and a potential …
no targeted therapy. The c-Myc protein is a master transcription factor and a potential …
c-Myc-Targeting PROTAC Based on a TNA-DNA Bivalent Binder for Combination Therapy of Triple-Negative Breast Cancer
X Li, Z Zhang, F Gao, Y Ma, D Wei… - Journal of the …, 2023 - pubmed.ncbi.nlm.nih.gov
Triple-negative breast cancer (TNBC) is highly aggressive with a poor clinical prognosis and
no targeted therapy. The c-Myc protein is a master transcription factor and a potential …
no targeted therapy. The c-Myc protein is a master transcription factor and a potential …